<SEC-DOCUMENT>0001193125-21-225235.txt : 20210727
<SEC-HEADER>0001193125-21-225235.hdr.sgml : 20210727
<ACCEPTANCE-DATETIME>20210727104452
ACCESSION NUMBER:		0001193125-21-225235
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210727
FILED AS OF DATE:		20210727
DATE AS OF CHANGE:		20210727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theratechnologies Inc.
		CENTRAL INDEX KEY:			0001512717
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			1130

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35203
		FILM NUMBER:		211116398

	BUSINESS ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
		BUSINESS PHONE:		514-336-7800

	MAIL ADDRESS:	
		STREET 1:		2015 PEEL STREET
		STREET 2:		5TH FLOOR
		CITY:			MONTREAL
		STATE:			A8
		ZIP:			H3A 1T8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d40108d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Private Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>under the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>July&nbsp;27, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35203</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>THERATECHNOLOGIES INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2015 Peel
Street, Suite 1100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Montr&eacute;al, Qu&eacute;bec, Canada </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H3A 1T8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of
principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
<FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F:</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9746;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check
mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Note: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7) only permits the submission in paper of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the
information to the Commission pursuant to Rule <FONT STYLE="white-space:nowrap">12g3-2(b)</FONT> under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule
<FONT STYLE="white-space:nowrap">12g3-2(b):</FONT> <FONT STYLE="white-space:nowrap">82-______________.</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THERATECHNOLOGIES INC. </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release Dated July&nbsp;23, 2021.</TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">THERATECHNOLOGIES INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jocelyn Lafond</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Legal Affairs</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: July&nbsp;27, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d40108dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g40108g61k27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Theratechnologies Establishes New
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-The-Market</FONT></FONT> Facility </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Montreal, QC &#150; July&nbsp;23, 2021
&#150; Theratechnologies Inc. (&#147;<B>Theratechnologies</B>&#148; or the &#147;<B>Company</B>&#148;) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced
that it has established an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> (&#147;<B>ATM</B>&#148;) equity program allowing Theratechnologies to issue and sell up to US&nbsp;$50&nbsp;million common
shares from treasury (the &#147;<B>Common Shares</B>&#148;) to the public at the Company&#146;s sole discretion and at the prevailing market price. Sales of the Common Shares under the ATM program will be made pursuant to the terms of a sales
agreement dated July&nbsp;23, 2021 with Cantor Fitzgerald&nbsp;&amp; Co (the &#147;<B>Agent</B>&#148;). The volume and timing of distributions under the ATM program, if any, will be determined at the Company&#146;s sole discretion, subject to
applicable regulatory limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">All Common Shares sold pursuant to the ATM will be sold through the Nasdaq Capital Market or another marketplace
upon which the Common Shares are listed, quoted or otherwise traded in the United States, at the prevailing market price at the time of sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">In
connection with the ATM, Theratechnologies has filed a prospectus supplement dated July&nbsp;23, 2021 (the &#147;<B>Prospectus Supplement</B>&#148;) with the securities regulatory authorities in each of the provinces of Canada and with the United
States Securities and Exchange Commission (&#147;<B>SEC</B>&#148;), which supplements the Company&#146;s Canadian short form base shelf prospectus dated November&nbsp;15, 2019 (the &#147;<B>Base Shelf Prospectus</B>&#148;), and the Company&#146;s
shelf registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-10</FONT> declared effective on November&nbsp;15, 2019 by the SEC. A copy of the Prospectus Supplement is available on our SEDAR profile at <U>www.sedar.com</U> or on EDGAR
at <U>www.sec.gov</U>. Alternatively, a copy of the Prospectus Supplement and accompanying base shelf prospectus are available upon request by contacting the Agent, Attn: Capital Markets, 499 Park Avenue, 4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, New York 10022 or by email at <U>prospectus@cantor.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This press release
shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of, the securities under the ATM program in any province, state or jurisdiction in which such offer, solicitation or
sale would be unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>About Theratechnologies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies
addressing unmet medical needs. Further information about Theratechnologies is available on the Company&#146;s website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>Forward-Looking Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This press release contains
forward-looking statements, within the meaning of Section&nbsp;21E of the <I>Securities Exchange Act of 1934</I>, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and
forward-looking information are collectively referred to herein as &#147;<B>forward-looking statements</B>&#148;), that are based on our management&#146;s beliefs and assumptions and on information currently available to our management. You can
identify forward-looking statements by terms such as &#147;may&#148;, &#147;will&#148;, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">
&#147;should&#148;, &#147;could&#148;, &#147;would&#148;, &#147;outlook&#148;, &#147;believe&#148;, &#147;plan&#148;, &#147;envisage&#148;, &#147;anticipate&#148;, &#147;expect&#148; and
&#147;estimate&#148;, or the negatives of these terms, or variations of them. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the offer and sale of Common Shares, and the use of
proceeds from the ATM program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Forward-looking statements are based upon a number of assumptions and include, but are not limited to, the
following: the <FONT STYLE="white-space:nowrap">Covid-19</FONT> pandemic will have limited adverse effect on the ATM program, the price, volume, timing and the regulatory approval for any distributions, the proceeds from the ATM program will be
allocated for the activities set forth herein and we will have enough funds to carry out our business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">We refer potential investors to the
&#147;Risk Factors&#148; section of our annual information form dated February&nbsp;24, 2021 available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov as an exhibit to our report on <FONT STYLE="white-space:nowrap">Form&nbsp;40-F</FONT> dated
February&nbsp;24, 2021 under Theratechnologies&#146; public filings for additional risks regarding the conduct of our business and Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to
put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or
circumstances or otherwise, except as may be required by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><B>For Investor Inquiries: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Philippe Dubuc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Senior Vice President and Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><U>pdubuc@theratech.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">514-336-7800</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Leah Gibson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">Senior
Director, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL">lgibson@theratech.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-356-1009</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g40108g61k27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g40108g61k27.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M%NE^)UE^P.XDBQOCD7# 'H?I7G_Q8U1[_5['0;4[F3#NH[NW"C\OYUDZ2)/
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:&>_>!2L*R*JJF1@G ')Q16_10.-.,=D?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
